Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy

References

• Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant. 2011;26(10):3391–3398. doi:10.1093/ndt/gfr048
   PubMed Web of Science ®Google Scholar
• Ji J, Wang Q, Huang T, et al. Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the treatment of pneumocystis jirovecii pneumonia in deceased donor kidney recipients. Infect Drug Resist. 2021;14:4913–4920. doi:10.2147/IDR.S339622
   PubMed Web of Science ®Google Scholar
• Iriart X, Bouar ML, Kamar N, et al. Pneumocystis pneumonia in solid-organ transplant recipients. J Fungi. 2015;1(3):293–331. doi:10.3390/jof1030293
   Google Scholar
• Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect. 2010;16(9):1375–1377. doi:10.1111/j.1469-0691.2010.03143.x
   PubMed Web of Science ®Google Scholar
• Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):CD005590. doi:10.1002/14651858.CD005590.pub3
   PubMed Web of Science ®Google Scholar
• Fishman JA, Gans H. AST infectious diseases community of practice. pneumocystis jiroveci in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13587. doi:10.1111/ctr.13587
   PubMedGoogle Scholar
• Yang H, Pang L, Hu X, et al. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study. J Pharm Pharm Sci. 2021;24:220–226. doi:10.18433/jpps31488
   PubMed Web of Science ®Google Scholar
• Prasad GVR, Beckley J, Mathur M, et al. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis. 2019;19(1):311. doi:10.1186/s12879-019-3944-0
   PubMedGoogle Scholar
• Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–782. doi:10.1128/CMR.17.4.770-782.2004
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii Pneumonia in human immunodeficiency virus-infected persons. Clin Infect Dis. 1999;29(4):775–783. doi:10.1086/520433
   PubMed Web of Science ®Google Scholar
• Ho JM, Juurlink DN. Considerations when prescribing trimethoprimsulfamethoxazole. CMAJ. 2011;183(16):1851–1858. doi:10.1503/cmaj.111152
   PubMed Web of Science ®Google Scholar
• Mitsides N, Greenan K, Green D, et al. Complications and outcomes of trimethoprimsulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology. 2014;19(3):157–163. doi:10.1111/nep.12201
   PubMed Web of Science ®Google Scholar
• Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995;13(1):239–250. doi:10.1200/JCO.1995.13.1.239
   PubMed Web of Science ®Google Scholar
• Heimpel H, Raghavachar A. Hematological side effects of co-trimoxazole. Infection. 1987;15(Suppl 5):S248–53. doi:10.1007/BF01643198
   PubMedGoogle Scholar
• Brakemeier S, Dürr M, Bachmann F, et al. Risk evaluation and outcome of Pneumocystis jirovecii pneumonia in kidney transplant patients. Transplant Proc. 2016;48(9):2924–2930. doi:10.1016/j.transproceed.2016.05.017
   PubMed Web of Science ®Google Scholar
• Peterson K, Berrigan L, Popovic K, et al. Lifelong, universal Pneumocystis jirovecii pneumonia prophylaxis: patient uptake and adherence after kidney transplant. Transpl Infect Dis. 2021;23(3):e13509. doi:10.1111/tid.13509
   PubMed Web of Science ®Google Scholar
• Chen RY, Li DW, Wang JY, et al. Prophylactic effect of low-dose trimethoprim- sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study. Int J Infect Dis. 2022;125:209–215. doi:10.1016/j.ijid.2022.10.004
   PubMed Web of Science ®Google Scholar
• Iriart X, Challan Belval T, Fillaux J, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant. 2015;15(1):190–199. doi:10.1111/ajt.12947
   PubMed Web of Science ®Google Scholar
• de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559–569. doi:10.1111/j.1399-3062.2011.00645.x
   PubMed Web of Science ®Google Scholar
• Borstnar S, Lindic J, Tomazic J, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience. Transplant Proc. 2013;45(4):1614–1617. doi:10.1016/j.transproceed.2013.02.107
   PubMed Web of Science ®Google Scholar
• Hosseini-Moghaddam SM, Shokoohi M, Singh G, et al. A multi-center case-control study of the effect of acute rejection and cytomegalovirus infection on Pneumocystis Pneumonia (PCP) in solid organ transplant recipients. Clin Infect Dis. 2019;68(8):1320–1326. doi:10.1093/cid/ciy682
   PubMed Web of Science ®Google Scholar
• Goto N, Takahashi-Nakazato A, Futamura K, et al. Lifelong prophylaxis with trimethoprim-sulfamethoxazole for prevention of outbreak of Pneumocystis jirovecii Pneumonia in kidney transplant recipients. Transplant Direct. 2017;3(5):e151. doi:10.1097/TXD.0000000000000665
   PubMedGoogle Scholar